A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00293761

Enrollment

109

Registered

2006-02-20

Start date

2006-01-31

Completion date

2006-05-31

Last updated

2016-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ocular Hypertension, Open-angle Glaucoma

Keywords

open-angle, glaucoma, ocular, hypertension

Brief summary

The purpose of the study is to determine whether a glaucoma therapy is safe and effective in treating patients with open-angle glaucoma or ocular hypertension

Interventions

DRUGTravoprost, Investigational

One drop in study eye once daily for 13 days

DRUGTravoprost (TRAVATAN)

One drop in study eye once daily for 13 days

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult patients of either sex of any race diagnosed with open-angle glaucoma (with or without pseudoexfoliation or pigment dispersion component) or ocular hypertension. * Other protocol-defined inclusion criteria may apply.

Exclusion criteria

* Under age 18. * Other protocol-defined

Design outcomes

Primary

Measure	Time frame
Mean IOP	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026